Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Dorff on the Benefit of Bright White Light Therapy on Obese Frailty in Prostate Cancer

February 13th 2021

Tanya Dorff, MD, discusses the effects of bright white light therapy on obese frailty in older men with prostate cancer.

Apalutamide Demonstrates Sustained Survival Benefit in mCSPC

February 13th 2021

February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.

Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC

February 12th 2021

Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Crossover Minimally Impacts OS Benefit Achieved With Darolutamide in ARAMIS Trial

February 12th 2021

February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.

PSMA-Targeted Agent Shows Potential Utility in Identifying Relapsed Prostate Cancer

February 12th 2021

February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.

Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPC

February 12th 2021

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

VERU-111 Elicits Early Efficacy Signals in Pretreated mCRPC

February 11th 2021

February 11, 2021 - The novel tubulin inhibitor VERU-111 demonstrated early antitumor activity and a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer who failed a prior androgen receptor–targeting agent.

Dr. Choudhury on the Rationale Behind Adding Pembrolizumab to Radium-223 in mCRPC

February 11th 2021

Atish D. Choudhury, MD, PhD, discusses the rationale behind combining pembrolizumab with radium-223 in patients with metastatic castration-resistant prostate cancer as part of a phase 2 clinical trial.

Oral Hormonal Therapy Breaks New Ground in Prostate Cancer

February 10th 2021

Neal D. Shore, MD, discusses the FDA approval of relugolix in prostate cancer.

Dr. Agarwal on the Significance of the LATITUDE Trial in Metastatic CSPC

February 2nd 2021

Neeraj Agarwal, MD, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate in patients with metastatic castration-sensitive prostate cancer.

Metastatic Prostate Cancer Paradigm Flourishes With Recent Progress

February 1st 2021

Data from 3 pivotal trials—PROfound, CARD, and HERO—have served to propel the metastatic prostate cancer treatment paradigm forward.

Shorter Course of SBRT Proves Safe, Effective in High-Risk Prostate Cancer

January 27th 2021

January 27, 2021 — A shorter course of stereotactic body radiotherapy has been shown to have encouraging efficacy with favorable toxicity when used in patients with high-risk prostate cancer in a multi-institutional, international setting.

Hormonal Agents Improve Survival in mCSPC, but Novel Targets Are Needed For Further Drug Development

January 26th 2021

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

Next-Generation AR Inhibitors Retain their Role in Nonmetastatic CRPC

January 18th 2021

Despite the availability of next-generation PET imaging modalities that can detect metastasis earlier, apalutamide, enzalutamide, and darolutamide remain the standard of care for patients with nonmetastatic castration-resistant prostate cancer who have a prostate-specific antigen doubling time of less than 10 months.

Pursuing New Paradigms in Prostate Cancer

January 14th 2021

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.

UCLA, UCSF Gain FDA Approval for Prostate Cancer Imaging Technique

January 13th 2021

New prostate cancer imaging technique is a ‘game changer’ that should become the standard of care, say researchers from UCLA and UCSF who validated its effectiveness.

Dr. Schweizer on the Results of the HERO Trial in Prostate Cancer

January 13th 2021

Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.

Dr. Gomella on the Role of Genetic Testing in Prostate Cancer

January 11th 2021

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Addition of Darolutamide May Augment Standard Treatment for Localized, Very High-Risk Prostate Cancer

January 11th 2021

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.

FDA Updates Label for Darolutamide in Nonmetastatic CRPC to Include OS Data

January 8th 2021

January 8, 2021 - The FDA has approved a supplemental new drug application to add overall survival and other secondary end point data from the phase 3 ARAMIS trial to the prescribing information for darolutamide for the treatment of patients with nonmetastatic prostate cancer.